Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
In the last 90 days, Cogent Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 322 institutions reported holding it in 13F filings for Q2 2026, worth $7.50B in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Cogent Biosciences, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 195
- +16 vs. Q2 2025
- Shares held
- 159.2M
- +23.7M (+17.5%) vs. Q2 2025
- Total value
- $2.29B
- +$1.31B (+135.0%) vs. Q2 2025
- New holders
- 40
- 88 more added
- Sold out
- 24
- 46 more reduced
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting COGT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 322 | $7.50B |
| Q1 2026 | 305 | $7.17B |
| Q4 2025 | 267 | $6.18B |
| Q3 2025 | 195 | $2.29B |
| Q2 2025 | 181 | $973.2M |
| Q1 2025 | 186 | $799.6M |
| Q4 2024 | 177 | $949.5M |
| Q3 2024 | 161 | $1.32B |
| Q2 2024 | 149 | $1.02B |
| Q1 2024 | 146 | $734.3M |
| Q4 2023 | 144 | $534.0M |
| Q3 2023 | 135 | $885.8M |
| Q2 2023 | 136 | $1.05B |
| Q1 2023 | 137 | $810.4M |
| Q4 2022 | 135 | $864.1M |
| Q3 2022 | 134 | $1.10B |
| Q2 2022 | 112 | $633.3M |
| Q1 2022 | 86 | $353.6M |
| Q4 2021 | 82 | $385.2M |
| Q3 2021 | 73 | $309.6M |
| Q2 2021 | 69 | $293.7M |
| Q1 2021 | 69 | $303.3M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Cogent Biosciences, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bollard Group LLC | 0 | $0 | 0.00% | −105,059−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −101,518−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −41,481−100.0% | Sold out |
| Birchview Capital, LP | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −33,784−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −26,385−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −23,668−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −23,194−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −18,230−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −17,438−100.0% | Sold out |
| Oxford Asset Management LLP | 0 | $0 | 0.00% | −15,931−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −13,727−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −13,038−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,428−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −6,099−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −31−100.0% | Sold out |
| Garde Capital, Inc. | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| CBIZ Investment Advisory Services, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| CIBC World Markets Corp | – | – | – | – | Not filed |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |